COVID-19: Significance of antibodies

Assadiasl, Sara; Fatahi, Yousef; Zavvar, Mahdi; Nicknam, Mohammad Hossein

doi:10.3233/hab-200429

Cited by 31 publications

(42 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease 2019 (COVID- 19) pandemic, stimulates an antibody response in both symptomatic and asymptomatic infection. 1,2 Healthcare workers (HCWs) were shown to be at increased risk of infection in previous coronavirus outbreaks, 3 making up 21.3% of total severe acute respiratory syndrome (SARS) infections and 18.9% of Middle East respiratory syndrome (MERS) infections. 4 Available data suggest they remain at high risk of COVID-19, 5 and more likely to show a positive COVID-19 antigen test result compared to the general population.…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 antibody seroprevalence in NHS healthcare workers in a large double-sited UK hospital

Ken‐Dror

Wade²,

Sharma

et al. 2021

Clinical Medicine

View full text Add to dashboard Cite

We determined the seroprevalence of SARS-CoV-2 antibodies in NHS healthcare workers (HCWs) in a cross-sectional study from a large general hospital located in a double-sited rural and semi-rural area. The sample size of 3,119 HCWs (mean age 43±13) consisted of 75.2% women, 61.1% White individuals and predominantly (62.4%) asymptomatic individuals. Seroprevalence of SARS-CoV-2 antibodies was 19.7%. Determinants of seropositivity were preceding symptomatic infection and non-White ethnicity. Regardless of staff role or sex, multivariate regression analysis revealed that non-White HCWs were three times (odds ratio [OR] 3.12, 95% confidence interval [CI] 2.53-3.86, P<0.001) more likely to have antibodies than White staff, and seven times (OR 7.10, 95% CI 5.72-8.87, P<0.001) more likely if there was a history of preceding symptoms. We report relatively high rates of seropositivity in all NHS healthcare workers. Non-White symptomatic HCWs were significantly more likely to be seropositive than their colleagues, independent of age, sex or staff role.

show abstract

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 antibody seroprevalence in NHS healthcare workers in a large double-sited UK hospital

Ken‐Dror

Wade²,

Sharma

et al. 2021

Clinical Medicine

View full text Add to dashboard Cite

show abstract

“…We demonstrated EG-COVID generated neutralizing antibodies against recombinant RBD protein. Since there was an approach whereby neutralizing antibodies directed primarily to RBD of spike protein could be applied as a complementary option to treat severe forms of COVID-19 (Assadiasl et al, 2020), the neutralizing antibody titer induced by EG-COVID could be an important indicator of an effective vaccine against SARS-CoV-2 infection.…”

Section: Discussionmentioning

confidence: 99%

“…The mRNA vaccine combines the benefits of the subunit vaccine and the live attenuated vaccine, and there is no risk associated with the live attenuated vaccine or the DNA vaccine (Reichmuth et al, 2016). Of all the viral antigens studied, the spike (S) and nucleocapsid (N) proteins are considered to be important immunogenic antigens for SARS-CoV-2 (Assadiasl, 2020). Among these, most vaccine candidates use the coronavirus glycosylated spike protein (S) as the primary antigenic target.…”

Section: Introductionmentioning

confidence: 99%

An mRNA vaccine against SARS-CoV-2: Lyophilized, liposome-based vaccine candidate EG-COVID induces high levels of virus neutralizing antibodies

Hong¹,

Kim²,

Park³

et al. 2021

Preprint

View full text Add to dashboard Cite

In addition to the traditional method of vaccine development, the mRNA coronavirus vaccine, which is attractive as a challenging vaccination, recently opened a new era in vaccinology. Here we describe the EG-COVID which is a novel liposome-based mRNA candidate vaccine that encodes the spike (S) protein of SARS-CoV-2 with 2P-3Q substitution in European variant. We developed the mRNA vaccine platform that can be lyophilized using liposome-based technology. Intramuscular injection of the EG-COVID elicited robust humoral and cellular immune response to SARS-CoV-2. Furthermore, sera obtained from mice successfully inhibited SARS-CoV-2 viral infection into Vero cells. We developed EG-COVID and found it to be effective based on in vitro data, and we plan to initiate a clinical trial soon. Since EG-COVID is a lyophilized mRNA vaccine that is convenient for transportation and storage, accessibility to vaccines will be significantly improved.

show abstract

“…Severe acute respiratory virus-2 (SARS-CoV-2), the virus responsible for COVID-19, has affected over 151 million people and contributed to over 3 million deaths [ 2 ]. SARS-CoV-2 is an enveloped positive-sense single-stranded RNA virus and is composed mainly of N (nucleocapsid), S (spike), M (membrane) and E (envelope) proteins [ 3 , 4 ]. Entrance into a host cell is induced by a connection between a spike protein and angiotensin-converting enzyme 2 (ACE2) receptor.…”

Section: Introductionmentioning

confidence: 99%

The Significance of COVID-19 Immunological Status in Severe Neurological Complications and Multiple Sclerosis—A Literature Review

Kulikowska

Kulczyńska-Przybik

Mroczko

et al. 2021

IJMS

View full text Add to dashboard Cite

SARS-CoV-2/Coronavirus 2019 (COVID-19) is responsible for the pandemic, which started in December 2019. In addition to the typical respiratory symptoms, this virus also causes other severe complications, including neurological ones. In diagnostics, serological and polymerase chain reaction tests are useful not only in detecting past infections but can also predict the response to vaccination. It is now believed that an immune mechanism rather than direct viral neuroinvasion is responsible for neurological symptoms. For this reason, it is important to assess the presence of antibodies not only in the serum but also in the cerebrospinal fluid (CSF), especially in the case of neuro-COVID. A particular group of patients are people with multiple sclerosis (MS) whose disease-modifying drugs weaken the immune system and lead to an unpredictable serological response to SARS-CoV-2 infection. Based on available data, the article summarizes the current serological information concerning COVID-19 in CSF in patients with severe neurological complications and in those with MS.

show abstract

COVID-19: Significance of antibodies

Cited by 31 publications

References 38 publications

SARS-CoV-2 antibody seroprevalence in NHS healthcare workers in a large double-sited UK hospital

SARS-CoV-2 antibody seroprevalence in NHS healthcare workers in a large double-sited UK hospital

An mRNA vaccine against SARS-CoV-2: Lyophilized, liposome-based vaccine candidate EG-COVID induces high levels of virus neutralizing antibodies

The Significance of COVID-19 Immunological Status in Severe Neurological Complications and Multiple Sclerosis—A Literature Review

Contact Info

Product

Resources

About